Citius Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of first in class critical care products focusing on oncology anti infectives in adjunct cancer care and unique prescription products. The company aims to secure leading market positions by offering therapies that address unmet medical needs while carrying lower development risk than typical new chemical entities. Its strategy centers on products protected by…
Citius Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of first in class critical care products focusing on oncology anti infectives in adjunct cancer care and unique prescription products. The company aims to secure leading market positions by offering therapies that address unmet medical needs while carrying lower development risk than typical new chemical entities. Its strategy centers on products protected by intellectual property and regulatory exclusivity that provide advantages over existing treatments.
Revenue currently comes from sales of the FDA approved lymphoma therapy LYMPHIR which was launched by the company's majority owned subsidiary Citius Oncology in December 2025. Additional revenue is anticipated from late stage candidates including Mino Lok a catheter lock solution for bloodstream infections Halo Lido a topical hemorrhoid treatment and Nove Cite a mesenchymal stem cell therapy for acute respiratory distress syndrome. The company may also earn milestone payments and royalties from licensing and partnership arrangements.
In the oncology space LYMPHIR competes with approved agents such as Mogamulizumab (Poteligeo) Brentuximab vedotin (Adcetris) Romidepsin (Istodax) and Vorinostat (Zolinza) for cutaneous T cell lymphoma. Its competitive advantage lies in a unique mechanism that delivers diphtheria toxin to IL 2 expressing cells while depleting regulatory T cells and in its orphan drug status and patent protection. For catheter infection Mino Lok offers a salvage alternative to the standard practice of removing and replacing contaminated central venous catheters facing competition mainly from procedural risks rather than approved drugs. Halo Lido seeks to become the first FDA approved prescription product for hemorrhoids a market currently dominated by over the counter options. Nove Cite targets acute respiratory distress syndrome where it differentiates itself from donor derived mesenchymal stem cell therapies through higher potency scalable production and consistent quality.
The company serves hospitals oncology clinics dermatology practices and hemodialysis centers. Specific distribution partners include Cardinal Health Cencora McKesson Corporation EVERSANA and Integris Pharma S. A. which support the commercialization of LYMPHIR in various regions.